Neuroprotective Potential of Peroxisome Proliferator Activated Receptor-α Agonist in Cognitive Impairment in Parkinson’s Disease: Behavioral, Biochemical, and PBPK Profile

Figure 1

(a) Retention trial latency in passive avoidance test. (b) Latency to enter the platform zone during retention trial in MWM test. ^∗𝑃<0.05 MPTP or MPTP + vehicle versus sham, ^∗∗𝑃<0.01 MPTP versus sham, ^#𝑃<0.05 MPTP + vehicle versus MPTP + feno 100 mg/kg treated group, ^##𝑃<0.01 MPTP versus feno 30 mg/kg or feno 100 mg/kg treated groups, ^@𝑃<0.05 MPTP versus MPTP + fenofibrate 100 mg/kg, ^@@𝑃<0.01 MPTP + vehicle versus MPTP + feno 100 mg/kg treated group. All readings are expressed as mean ± SEM (𝑛=8 to 12).

(a)

(b)